Family · Pharmaceutical analytical standards
Tolvaptan
An oral vasopressin V2 receptor antagonist, blocking the antidiuretic hormone: it helps the kidneys get rid of excess water and was approved in the US in 2009 for hyponatraemia, meaning too little sodium in the blood. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?In 2014 Japan approved it as the world's first drug treatment to slow autosomal dominant polycystic kidney disease.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
